ERCC1 and claudin-4 expression in gastric cancer tumorogenesis and development have clinical and pathological relevance.

Background: Gastric cancer is a significant health and social problem with a high risk of local recurrence. The goal of this study was to look at the immunohistochemistry expression of ERCC1 and claudin-4 in gastric cancer, as well as the relationship with clinicopathologic items and survival in gastric cancer, in order to see how these proteins affect progression and tumorogenesis.
Materials and methods: A total of 155 postoperative specimens were collected, analyzed, and utilized to create tissue microarray blocks from patients diagnosed with stomach cancer. Claudin-4 and ERCC1 immunohistochemical expression were investigated and their relationship with clinicopathological characteristics and patient prognosis was determined.
Results: Claudin-4 and ERCC1 were found in gastric cancer tissues in 54.2 percent and 41.3 percent, respectively. Both proteins were shown to be associated with TNM stage, the number of positive lymph nodes (N), and the depth of invasion (T). Despite the fact that ERCC1 had a strong relationship with histological type and grade, as well as Lauren categorization, claudin-4 did not. High claudin-4 expression was linked to a greater survival rate (58.9%) and an increase in OS (24.5 months) and DFS (18.9 months) in the survival study, but ERCC1 had no correlation with life expectancy (except for DFS on multivariate analysis).
Conclusion: The findings of this retrospective analysis show that the ERCC1 gene polymorphism and Claudin-4 have a significant impact on gastric cancer pharmacokinetics and treatment outcome. Also it may be useful biomarkers to predict the clinical outcomes and can select the cases who receive more aggressive protocols.